Option, License and Collaboration Agreement entered into in 2020, giving Gilead an exclusive license to the anti-PD-1 program and option rights to clinical programs, with cost-sharing and royalties.
| Officer | Age | In this role | Joined | Source |
|---|---|---|---|---|
|
Terry Rosen, Ph.D.
Also a director
Chief Executive Officer, Director and Chairman
|
66 | Not stated | Not stated | |
|
Robert C. Goeltz, II
Chief Financial Officer
|
53 |
Since 2020
6 years
|
Not stated | |
|
Juan Carlos Jaen, Ph.D.
President
|
68 |
Since 2015
11 years
|
Not stated | |
|
Richard Markus, M.D., Ph.D.
Chief Medical Officer
|
60 |
Since 2025
1 year
|
2025 | |
|
Carolyn Tang
General Counsel
|
47 |
Since 2019
7 years
|
2017 | |
|
Alexander Azoy
Chief Accounting Officer
Title from the Form 4 dated Aug 21, 2026
|
Not stated | Not stated | Not stated |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Option, License and Collaboration Agreement entered into in 2020, giving Gilead an exclusive license to the anti-PD-1 program and option rights to clinical programs, with cost-sharing and royalties.
Investor Rights Agreement entered into in 2020, under which Gilead designated three individuals to the board of directors and a Science Committee was established.
Gilead acquired shares in the company's February 2025 underwritten equity offering from the underwriters.
Employment of a son of the CEO as Director in the chemistry department, with 2025 cash compensation, option and restricted stock unit grants.
Employment of another son of the CEO as Principal Investigator in the biology department, with 2025 cash compensation, option and restricted stock unit grants.
Employment of the CEO's daughter-in-law as Principal Investigator in the bioinformatics department, with 2025 cash compensation, option and restricted stock unit grants.
Loading...